SQLite Web: event_store.db

Update row 13867 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-10T03:04:31.796915+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:5b9dae87294b49b7","evidence_event_ids":["evt_64683ea5ff28"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-149827.txt","as_of":"2026-04-10T03:04:31.796915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-149827.txt","company":"SPRUCE BIOSCIENCES, INC.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-149827.txt","article_chars":4179,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_ec260bb94b984e73","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-149827.txt","content_type":"text/plain","enriched_at":"2026-04-10T03:33:20.785827+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"DEFA14A","final_url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-149827.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-149827.txt","source_event_id":"evt_64683ea5ff28","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEFA14A","fp":"c0875729919fa03b","kind":"sec_filing","published_at":"20260409","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-09","2026-04-10","May 20, 2026","May 21, 2026","May 7, 2026","2029 annual meeting","December 31, 2026"],"entities":[{"asset_class":"equity","name":"Spruce Biosciences, Inc.","relevance":"high","symbol":"SPRB","type":"issuer"},{"asset_class":"other","name":"BDO USA, P.C.","relevance":"medium","symbol":"","type":"auditor"},{"asset_class":"other","name":"Michael Grey","relevance":"medium","symbol":"","type":"director_nominee"},{"asset_class":"other","name":"Camilla V. Simpson, M.Sc.","relevance":"medium","symbol":"","type":"director_nominee"},{"asset_class":"other","name":"Javier Szwarcberg, M.D., MPH","relevance":"medium","symbol":"","type":"director_nominee"}],"event_type":"listing","information_gaps":["What specifically changed versus a prior known state is not provided in the signal text (no prior filing comparison content included).","The filing\u2019s \u201cAmendment No.\u201d field is shown as blank (\u201c(Amendment No. )\u201d), so the amendment number is unknown from the provided text.","The filing does not include the full proxy statement details (only an overview/notice and voting items are shown in the provided excerpt).","No explicit financial guidance or financial implications are stated in the provided text beyond advisory votes and auditor ratification."],"key_facts":["The filing is a Schedule 14A proxy statement (DEFA14A) for Spruce Biosciences, Inc. marked as \u201cDefinitive Additional Materials.\u201d","The filing indicates no fee required for the submission.","The annual meeting is scheduled for May 21, 2026 at 10:00 A.M. Pacific Time (with reference to any adjournment/postponement).","Stockholders are instructed that votes are available online at www.virtualshareholdermeeting.com/SPRB2026 and via www.ProxyVote.com.","Voting items listed: (1) elect three Class III directors (Michael Grey; Camilla V. Simpson, M.Sc.; Javier Szwarcberg, M.D., MPH) until the 2029 annual meeting; (2) ratify BDO USA, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026; (3) advisory approval of named executive officer compensation; (4) advisory vote on preferred frequency of stockholder advisory votes on executive compensation.","The notice states \u201cBoard Recommends For\u201d for the listed advisory items (as shown in the provided text).","A request for paper/email copies is described as available by requesting prior to May 7, 2026."],"numeric_claims":[{"label":"Annual meeting date","value":"May 21, 2026"},{"label":"Annual meeting time (PT)","value":"10:00 A.M. Pacific Time"},{"label":"Vote deadline","value":"May 20, 2026 11:59 P.M. Eastern Time"},{"label":"Fiscal year end","value":"December 31, 2026"},{"label":"Director term until","value":"2029 annual meeting of stockholders"}],"primary_claim":"SPRB (Spruce Biosciences, Inc.) filed Form DEFA14A on 2026-04-09/2026-04-10, containing an overview of proposals for the May 21, 2026 annual meeting and voting instructions.","relevance_score":0.45,"sentiment":"neutral","source_quality":"high","summary":"Spruce Biosciences, Inc. filed a definitive additional proxy-related filing (DEFA14A) providing notice/overview of voting items for its 2026 annual meeting. The filing includes the meeting date/time and lists four proposals for stockholder vote.","topics":["SEC filing","proxy statement","annual meeting","director election","independent auditor ratification","executive compensation advisory vote","say-on-pay frequency advisory vote","stockholder voting instructions"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEFA14A \u00b7 SPRUCE BIOSCIENCES, INC. \u00b7 Filed 20260409","ticker":"SPRB","tickers":["SPRB"],"title":"SPRB filed DEFA14A","url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-149827.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel